A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs IMM 124E (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Immuron
- 13 Mar 2018 According to an Immuron media release, the company is planning to share data from this trial in roadshow to investment institutions, analysts and shareholders.
- 07 Mar 2018 Topline results presented in the Immuron Media Release.
- 09 Nov 2017 According to an Immuron media release, Last Patient Last Visit has been completed and data due in the first quarter of next year (Q1 CY2018).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History